奥拉帕利单药治疗gBRCAm、HER2阴性转移性乳腺癌的真实世界IIIb期LUCY试验中期分析
LUCY是一项开放标签、单臂IIIb期试验,评估奥拉帕利(300mg每日两次)在gBRCAm、HER2阴性转移性乳腺癌患者中的临床有效性。中期分析显示,252例入组患者的中位研究者评估PFS为8.11个月(95%CI 6.93-8.67),临床缓解率为48.6%,安全性与此前研究一致。
要点
- 奥拉帕利在gBRCAm、HER2阴性mBC中位PFS为8.11个月(95%CI 6.93-8.67)。
- 研究者评估的临床缓解率为48.6%。
- ≥3级TEAE发生率为25.4%,贫血最常见(13.1%)。
核心结论
- 奥拉帕利在gBRCAm、HER2阴性转移性乳腺癌患者中具有临床有效性,安全性与此前研究一致。
研究设计与样本
- 开放标签、单臂IIIb期LUCY试验,计划在160例PFS事件后进行中期分析。
- 筛查563例患者,入组252例gBRCAm患者并接受至少一剂奥拉帕利(300mg,每日两次)。
- 入组患者为gBRCAm、HER2阴性mBC,既往在(新)辅助/转移阶段接受过紫杉类和/或蒽环类,且mBC化疗线数不超过2线。
- 激素受体阳性mBC患者需在辅助/转移阶段至少一线内分泌治疗进展且不适合进一步内分泌治疗。
主要发现
- 中位研究者评估PFS为8.11个月(95%CI 6.93-8.67;166/252事件,成熟度65.9%)。
- 研究者评估的临床缓解率为48.6%。
- 至首次后续治疗或死亡的中位时间为9.66个月(95%CI 8.67-11.14)。
- 最常见TEAE(>20%患者)为恶心、贫血、乏力、呕吐和疲劳。
- 11例患者(4.4%)因TEAE终止治疗;≥3级TEAE发生于64例(25.4%),包括贫血(33例;13.1%)。
临床怎么用
- 对于既往接受过紫杉类和/或蒽环类且化疗线数有限的gBRCAm、HER2阴性mBC患者,奥拉帕利单药可作为临床实践中的治疗选择。
- 治疗期间需关注恶心、贫血、乏力等常见不良事件,尤其是贫血的监测与管理。
局限性
- 单臂设计,无对照,无法直接比较奥拉帕利与其他治疗方案的疗效差异。
- 中期分析结果,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice. METHODS: This open-label, single-arm trial of olaparib (300 mg, twice daily) enrolled patients with BRCAm, HER2-negative mBC who had received taxane and/or anthracycline in the (neo)adjuvant/metastatic setting and not more than two lines of prior chemotherapy for mBC. Patients with hormone receptor-positive mBC had progressed on at least one line of endocrine therapy in an adjuvant/metastatic setting and were unsuitable for further endocrine treatment. This interim analysis was planned after 160 PFS events. RESULTS: Of 563 patients screened, 252 patients with gBRCAm were enrolled and received at least one dose of olaparib. The median investigator-assessed PFS was 8.11 months (95% confidence interval [CI], 6.93-8.67; 166/252 events [65.9% maturity]). The investigator-assessed clinical response rate was 48.6%, and median time to first subsequent treatment or death was 9.66 months (95% CI, 8.67-11.14). The most common treatment-emergent adverse events (TEAEs; >20% patients) were nausea, anaemia, asthenia, vomiting and fatigue. Eleven patients (4.4%) discontinued treatment because of a TEAE. Grade 3 or higher TEAEs occurred in 64 patients (25.4%), including anaemia (33 patients; 13.1%). CONCLUSION: Olaparib was clinically effective in patients with gBRCAm, HER2-negative mBC with safety outcomes consistent with previous findings. ClinicalTrials.gov identifier: NCT03286842.
引用
- Gelmon KA, Fasching PA, Couch FJ, et al. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer. 2021. PMID: 34087573. doi:10.1016/j.ejca.2021.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。